JPRN-UMIN000026001
Recruiting
未知
A phase II study of the dose reduction and shortening of duration of immunosuppressant after HLA-haploloidentical transplantation with post-transplantation cyclophosphamide following myeloablative conditioning - JSCT-Haplo17 MAC
JSCT0 sites42 target enrollmentApril 1, 2017
Conditionshematologic malignancies
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- hematologic malignancies
- Sponsor
- JSCT
- Enrollment
- 42
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Patients who are positive for HIV antibody. 2\. Patients with active other malignancies. 3\. Patients with active infectious disease. 4\. Women who are pregnant, of childbearing potential, or lactating. 5\. Patients who experienced serious hypersensitivity or anaphylaxis to cyclophosphamide, fludarabine, tacrolimus, mycophenolate mofetil. 6\. Patients who has a prior history of allogeneic transplantation. 7\. Positive anti\-donor HLA antibody. 8\. Patients who need chemotherapy within 13 days before transplantation. 9\. Patients who are not eligible for this study at the discretion of the investigator.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
A phase II study of the dose reduction and shortening of duration of immunosuppressant after HLA-haploidentical transplantation with post-transplantation cyclophosphamide following reduced-intensity conditioninghematologic malignanciesJPRN-UMIN000026002JSCT55
Active, not recruiting
Phase 1
A Study, in which patients with advanced hepatocellular carcinoma (HCC) and preserved liver function are treated with a reduced starting dose ofcabozantinib, followed by an increase of dose, after treatment failure of one previous therapyAdvanced stage hepatocellular carcinoma (HCC) patients with preserved liver function in second line therapyTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2020-000775-20-DEFrankfurter Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest40
Recruiting
Not Applicable
Study of efficacy and safety of dose reduction in the oral cavity by target volume definition using PET/CT for intensity-modulated radiation therapy of head and neck cancersHead-and-neck cancerJPRN-UMIN000033007Juntendo University,Graduate School of Medicine,Department of Radiation Oncology10
Active, not recruiting
Phase 2
Shortened Course Adjuvant Radiotherapy Following TORSHPV-Associated Oropharyngeal Squamous Cell CarcinomaNCT05714657Abramson Cancer Center at Penn Medicine104
Active, not recruiting
Not Applicable
ow doses of Rituximab in Graves orbitopathyActive moderate to severe Graves OrbitopathyMedDRA version: 14.1Level: PTClassification code 10060742Term: Endocrine ophthalmopathySystem Organ Class: 10015919 - Eye disordersTherapeutic area: Diseases [C] - Hormonal diseases [C19]EUCTR2012-001980-53-ITFONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO10